Business
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. “We are pleased to welcome Jim to our Board of Directors,” said Kleanthis G. Xanthopoulos, Chairman of the Board of Directors. “His deep expertise in drug development and commercialization will make him an invaluable asset as we continue to build a proven team of industry experts to rapidly advance the development and commercialization of rademikibart.” Barry Quart, Chief Executive Officer of Connect Biopharma added, “Rademikibart has demonstrated a differentiated clinical profile that would uniquely position it to rapidly treat the millions of patients with asthma or COPD who experience an acute exacerbation annually. We look forward to leveraging Jim’s strategic and commercial acumen as we advance our Phase 2 Seabreeze STAT studies towards clinical data expected in the first half of 2026.” “I am delighted to join Connect and have been impressed by the potential of rademikibart to transform the treatment paradigm for acute and chronic asthma and COPD patients. I look forward to working closely with the team to guide the Company’s development efforts and chart a course for long-term commercial success,” said Mr. Schoeneck. Mr. Schoeneck is an accomplished biotech leader with more than 40 years of experience developing and commercializing breakthrough medicines and guiding companies through significant transformation, including both organic and inorganic growth. He currently serves as Chairman of the Board of Directors of each of FibroGen, Inc. and Calidi Biotherapeutics, Inc. Mr. Schoeneck previously served as Chief Executive Officer and a member of the Board of Directors of each of Depomed, Inc., BrainCells Inc., ActivX Biosciences, Inc. and Prometheus Laboratories Inc., and Chairman of the National Board...